Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma

Neoplasia

Volumn 6, Issue 5, 2004, Pages 449-456

  Dinis Ribeiro, Marío ^a,b,c   Da Costa Pereira, Altamiro ^b   Lopes, Carlos ^a   Barbosa, Joana ^a   Guilherme, Mateus ^a   Moreira Dias, Luís ^a   Lomba Viana, Helena ^a   Silva, Rui ^a   Abreu, Nuno ^a   Lomba Viana, Rafael ^a  

^a Institute of Radiation Oncology   (Portugal)

^b Porto Faculty of Medicine   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

Disease management; Pepsinogens; Precancerous conditions; Receiver operating characteristic curve; Stomach neoplasms

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATROPHIC GASTRITIS; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; EPITHELIUM DYSPLASIA; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ROC CURVE; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH EPITHELIUM; VALIDATION PROCESS;

EID: 6944244815     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.03505     Document Type: Article

References (44)

1. Carneiro F, Machado JC, David L, Reis C, Nogueira AMMF, and Sobrinho-Simões M (2001). Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev 10, 101-102.
2. Everett SM and Axon ATR (1997). Early gastric cancer in Europe. Gut 41, 142-150.
3. Di Gregorio C, Morandi P, Fante R, and De Caetani C (1993). Gastric dysplasia. A follow-up study. Am J Gastroenterol 88, 1714-1719.
4. Samloff IM (1971). Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 61, 185-188.
5. Samloff IM and Liebman WM (1973). Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 65, 36-42.
6. Basson M and Modlin I (1988). Pepsinogen: biological and pathophysiologic significance. J Surg Res 44, 82.
7. Fukunaga H, Hovita K, and Otsuka N (1989). Fundamental and clinical study for pepsinogen I and II RIABEAD Kit. Igaku-To-Yakugaku Med Pharm Sci 21, 905-914.
8. Huang S, Miki K, Furihata C, Ichinote M, Shimizu S, and Oka H (1988). Enzyme-like immunosorbent assays for serum pepsinogens I and II using monoclonal antibodies - with data on peptic ulcer and gastric cancer. Clin Chem Acta 175, 37.
9. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, Johnstone I, and Parsonnet J (2001). Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomark Prev 10, 107-112.
10. Nietsch H, Nametaka T, Rubin CE, Miki K, and Kimmey MB (2001). Gastric cancer screening in asymptomatic Japanese Americans using serum pepsinogen levels and endoscopy. Endoscopy 53, AB209.
11. Miki K, Ichinose M, Kawamura N, Matsushima M, Ahmad HB, Kimura M, Sano J, Tashiro T, Kakei N, Oka H, Furihata C, and Takahashi K (1989). The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronica gastritis in Japanese subjects. Jpn J Cancer Res 1, 45-50.
12. Miki K, Ichinose M, Simizu A, Huang SC, Oka H, Furihata C, Matsushima T, and Takahashi K (1987). Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 22, 133-140.
13. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, and Harkonen M (2000). Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 35, 950-956.
14. Webb PM, Hengels KJ, Moller H, Newell DG, Palli D, Elder JB, Coleman MP, De Backer G, and Forman D (1994). The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. Gastroenterology 107, 1335-1344.
15. Fahey MT, Hamada GS, Nishimoto IN, Kowalski LP, Iriya K, Gama-Rodrigues JJ, and Tsugane S (2000). Ethnic differences in serum pepsinogen levels among Japanese and non-Japanese Brazilian gastric cancer patients and controls. Cancer Detect Prev 24, 564-571.
16. Kato I, Miki K, Munoz N, Vivas JH, Lopez G, Peraza S, Carillo E, Castro D, Andrade O, and Sanchez V (1995). Determinants of plasma pepsinogen levels in a population at high risk for stomach cancer in Venezuela. Int J Cancer 62, 512-518.
17. Zhang L, Blot WJ, You WC, Chang YS, Kneller RW, Jin ML, Li JY, Zhao L, Liu WD, Zhang JS, Ma JL, Samloff IM, Correa P, Blaser MJ, Xu GW, and Fraumeni JF Jr(1996). Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomark Prev 5, 627-630.
18. Dinis-Ribeiro M, Costa-Pereira A, Lopes C, Lara-Santos L, Guilherme M, Moreira-Dias L, Lomba-Viana H, Ribeiro A, Santos C, Soares J, Mesquita N, Silva R, and Lomba-Viana R (2003). Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 57, 498-504.
19. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez L, Halperin D, Ley C, and Parsonnet J (1999). Interobserver variability in application of the revised Sydney classification of gastritis. Hum Pathol 30, 1431-1434.
20. Filipe MI, Barbatis C, Sandey A, and Metz DC (1998). Expression of intestinal mucin antigens in the gastric epithelium and its relationship with malignancy. Hum Pathol 19, 19-26.
21. Stemmerman GN and Fenoglio-Preiser C (2002). Gastric carcinoma distal to the cardia: a review of the epidemiological pathology of the precursors to a preventable cancer. Pathology 34, 494-503.
22. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, and Genta RM (2000). Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 95, 1431-1438.
23. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, and Yamabe H (2000). The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47, 251-255.
24. Barbosa J, Dinis-Ribeiro M, Guilherme M, Filipe T, Lomba-Viana R, Guimaræs MA, and Lopes C (2003). Use of Helicobacter pylori-specific antibodies in the diagnosis of intestinal metaplasia and dysplasia. Br J Biomed Sci 60, 175-179.
25. Dixon M (1997). Helicobacter pylori gastritis: pathology and progression. Int Med Publ, 110-118.
26. El-Zimaity HM, Ramchatesingh J, Saeed M, and Graham D (2001). Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 54, 679-683.
27. Genta RM, Gurer IE, Graham DY, Krishnan B, Segura AM, Gutierrez O, Kim JG, and Burchette JL Jr (1996). Adherence of Helicobacter pylori to areas of incomplete intestinal metaplasia in the gastric mucosa. Gastroenterology 111, 1206-1211.
28. Ferlay J, Bray F, Sankila R, and Parkin DM (1999). Cancer Incidence, Mortality and Prevalence in the European Union 1997. IARC Cancer Base No. 4 IARC Press, Lyon.
29. Conchillo JM, Houben G, deBruine A, and Stockbrugger RW (2001). Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma? Eur J Cancer Prev 10, 307-312.
30. Whiting JL, Signedsson A, Rowlands DC, Hallissey MT, and Fielding JW (2002). The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 50, 378-381.
31. Lahner E, Caruana P, D'Ambra G, Ferraro G, Di Giulio E, Delle Fave G, Bordi C, and Annibale B (2001). First endoscopic follow-up in patients with predominant atrophic gastritis: when should it be done? Gastrointest Endosc 53, 443-448.
32. Corral MJC, Pardo-Mindan FJ, Razquin S, and Ojeda C (1990). Risk of cancer in patients with gastric dysplasia. Follow-up study of 67 patients. Cancer 65, 2078-2085.
33. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, and Ruiz B (1990). Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 50, 4737-4740.
34. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process - first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52, 6735-6740.
35. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, and Moreira-Diaz L (2004). A follow-up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 57, 177-182.
36. You WC, Li JY, Blot WJ, Chang YS, Jin ML, Gail MH, Zhang L, Liu WD, MaJL, Hu YR, Mark SD, Correa P, Fraumeni JF Jr, and Xu GW (1999). Evolution of precancerous lesions in a rural Chinese population at high-risk of cancer. Int J Cancer 83, 615-619.
37. Bouma BE, Tearney GJ, Compton CC, and Nishioka NS (2000). High-resolution imaging of the human esophagus and stomach in vivo using optical coherence tomography. Gastrointest Endosc 51, 467-473.
38. Sivak MV Jr, Kobayashi K, Izatt JA, Rollins AM, Ung-Runyawee R, Chak A, Wong RC, Isenberg GA, and Willis J (2000). High-resolution endoscopic imaging of the GI tract using optical coherence tomography. Gastrointest Endosc 51, 474-479.
39. Tajiri H, Doi T, Endo H, Nishina T, Terao T, Hyodo I, Matsuda K, and Yagi K (2001). The application of magnifying endoscopy to gastric cancer diagnosis: a prospective study. Endoscopy 53, AB123.
40. Goldschmiedt M, Barnett CC, Schwarz BE, Karnes WE, Redfern JS, and Feldman M (1991). Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterology 101, 977-990.
41. Serrano MT, Lanas AI, Lorent S, and Sainz R (1997). Cytokine effects on pepsinogen secretion from human cells. Gut 40, 42-48.
42. Lorente S, Doiz O, Trinidad Serrano M, Castillo J, and Lanas A (2002). Helicobacter pylori stimulates pepsin secretion from isolated human peptic cells. Gut 50, 13-18.
43. Osawa H, Inoue F, and Yoshida Y (1996). Inverse relation of serum Helicobacter pylori antibody titres and extent of intestinal metaplasia. J Clin Pathol 49, 112-115.
44. Fukuda H, Saito D, Hayashi S, Hisai H, Ono H, Yoshida S, Oguro Y, Noda T, Sato T, and Katoh M (1995). Helicobacter infection, serum pepsinogens levels and gastric cancer: a case-control study in Japan. Jpn J Cancer Res 86, 64-71.